ArticleJournal of immunology (Baltimore, Md. : 1950)2008
Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 45 citations in OpenAlex.
- Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Human gene therapy · 2018Article
- Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo.Gene therapy · 2017Article
- The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.Therapeutic advances in vaccines · 2013Article
- Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.Human vaccines & immunotherapeutics · 2013Review
- The future of human DNA vaccines.Journal of biotechnology · 2012Review
- Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.Human vaccines & immunotherapeutics · 2012Article
- Targeted treatments for cervical cancer: a review.OncoTargets and therapy · 2012Article
- Advances in Gene Delivery Systems.Pharmaceutical medicine · 2011Article
- Therapeutic HPV DNA vaccines.Immunologic research · 2010Review
- DNA vaccines for cervical cancer.American journal of translational research · 2010Article
- TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy.Journal of biomedicine & biotechnology · 2010Review
- Perspectives for preventive and therapeutic HPV vaccines.Journal of the Formosan Medical Association = Taiwan yi zhi · 2010Review
- Polymeric Materials for Gene Delivery and DNA Vaccination.Advanced materials (Deerfield Beach, Fla.) · 2009Article
- Physical approaches for nucleic acid delivery to liver.The AAPS journal · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 4 countries.
Funding
Abstract
Administration of DNA vaccines via gene gun has emerged as an important form of Ag-specific immunotherapy. The MHC CIITA is a master regulator of MHC class II expression and also induces expression of class I molecules. We reasoned that the gene gun administration of CIITA DNA with DNA vaccines employing different strategies to improve MHC I and II processing could enhance DNA vaccine potency. We observed that DC-1 cells transfected with CIITA DNA lead to higher expression of MHC I and II molecules, leading to enhanced Ag presentation through the MHC I/II pathways. Furthermore, our data suggested that coadministration of DNA-encoding calreticulin (CRT) linked to human papillomavirus (HPV) 16 E6 Ag (CRT/E6) with CIITA DNA leads to enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. In addition, coadministration of the combination of CRT/E6 DNA with CIITA DNA and DNA encoding the invariant chain (Ii) linked to the pan HLA-DR-reactive epitope (Ii-PADRE) further enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. Treatment with the combination vaccine was also shown to enhance the antitumor effects and to prolong survival in TC-1 tumor-bearing mice. Vaccination with the combination vaccine also led to enhanced E6-specific CD8(+) memory T cells and to long-term protection against TC-1 tumors and prolonged survival in vaccinated mice. Thus, our findings suggest that the combination of CIITA DNA with CRT/E6 and Ii-PADRE DNA vaccines represents a potentially effective means to combat tumors in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.